Cargando…
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study
BACKGROUND: Vaccination with dendritic cells (DC) loaded with tumor antigens elicits tumor-specific immune responses capable of killing cancer cells without inducing meaningful side-effects. Patients with advanced melanoma enrolled onto our phase II clinical studies have been treated with autologous...
Autores principales: | de Rosa, Francesco, Ridolfi, Laura, Ridolfi, Ruggero, Gentili, Giorgia, Valmorri, Linda, Nanni, Oriana, Petrini, Massimiliano, Fiammenghi, Laura, Granato, Anna Maria, Ancarani, Valentina, Pancisi, Elena, Soldati, Valentina, Cassan, Serena, Riccobon, Angela, Parisi, Elisabetta, Romeo, Antonino, Turci, Livia, Guidoboni, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223722/ https://www.ncbi.nlm.nih.gov/pubmed/25053129 http://dx.doi.org/10.1186/1479-5876-12-209 |
Ejemplares similares
-
Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
por: Ridolfi, Laura, et al.
Publicado: (2018) -
FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
por: Fiammenghi, Laura, et al.
Publicado: (2010) -
Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”
por: Ridolfi, Laura, et al.
Publicado: (2011) -
Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis
por: Ridolfi, Laura, et al.
Publicado: (2010) -
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients
por: Ridolfi, Laura, et al.
Publicado: (2013)